References
1. Zaccardi F, Webb D, Htike Z, Youssef D, Khunti K, Davies M. Efficacy
and safety of sodium-glucose co-transporter-2 inhibitors in type 2
diabetes mellitus: systematic review and network meta-analysis.
Diabetes, obesity & metabolism 2016; 18: 783-94.
2. Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M, Mosenzon O,
Kato E, Cahn A, Furtado R, Bhatt D, Leiter L, McGuire D, Wilding J,
Sabatine M. SGLT2 inhibitors for primary and secondary prevention of
cardiovascular and renal outcomes in type 2 diabetes: a systematic
review and meta-analysis of cardiovascular outcome trials. Lancet
(London, England) 2019; 393: 31-39.
3. Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D,
Edwards R, Agarwal R, Bakris G, Bull S, Cannon C, Capuano G, Chu P, de
Zeeuw D, Greene T, Levin A, Pollock C, Wheeler D, Yavin Y, Zhang H,
Zinman B, Meininger G, Brenner B, Mahaffey K. Canagliflozin and Renal
Outcomes in Type 2 Diabetes and Nephropathy. The New England journal of
medicine 2019; 380: 2295-306.
4. Bauersachs J, de Boer R, Lindenfeld J, Bozkurt B. The year in
cardiovascular medicine 2021: heart failure and cardiomyopathies.
European heart journal 2022; 43: 367-76.
5. Mahaffey K, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw
W, Fabbrini E, Sun T, Li Q, Desai M, Matthews D. Canagliflozin for
Primary and Secondary Prevention of Cardiovascular Events: Results From
the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Circulation 2018; 137: 323-34.
6. Mahaffey K, Jardine M, Bompoint S, Cannon C, Neal B, Heerspink H,
Charytan D, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw
D, Greene T, Levin A, Pollock C, Sun T, Wheeler D, Yavin Y, Zhang H,
Zinman B, Rosenthal N, Brenner B, Perkovic V. Canagliflozin and
Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and
Chronic Kidney Disease in Primary and Secondary Cardiovascular
Prevention Groups. Circulation 2019; 140: 739-50.
7. FDA confirms increased risk of leg and foot amputations with the
diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). In,
2017.
8. FDA removes Boxed Warning about risk of leg and foot amputations for
the diabetes medicine
canagliflozin (Invokana, Invokamet, Invokamet XR). In.
9. Fulcher G, Matthews D, Perkovic V, de Zeeuw D, Mahaffey K, Mathieu C,
Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G,
Neal B. Efficacy and safety of canagliflozin when used in conjunction
with incretin-mimetic therapy in patients with type 2 diabetes.
Diabetes, obesity & metabolism 2016; 18: 82-91.
10. Neal B, Perkovic V, de Zeeuw D, Mahaffey K, Fulcher G, Ways K, Desai
M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G,
Matthews D. Efficacy and safety of canagliflozin, an inhibitor of
sodium-glucose cotransporter 2, when used in conjunction with insulin
therapy in patients with type 2 diabetes. Diabetes care 2015; 38:
403-11.
11. Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association
Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity
Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med 2018;
178: 1190-98.
12. Kavanagh N, Ryan E, Widaa A, Sexton G, Fennell J, O’Rourke S, Cahill
K, Kearney C, O’Brien F, Kerrigan S. Staphylococcal Osteomyelitis:
Disease Progression, Treatment Challenges, and Future Directions.
Clinical microbiology reviews 2018; 31.
13. Prokesch BC, TeKippe M, Kim J, Raj P, TeKippe EM, Greenberg DE.
Primary osteomyelitis caused by hypervirulent Klebsiella pneumoniae. The
Lancet Infectious Diseases 2016; 16: e190-e95.
14. Shone A, Burnside J, Chipchase S, Game F, Jeffcoate W. Probing the
validity of the probe-to-bone test in the diagnosis of osteomyelitis of
the foot in diabetes. Diabetes care 2006; 29: 945.
15. Schwegler B, Stumpe K, Weishaupt D, Strobel K, Spinas G, von
Schulthess G, Hodler J, Böni T, Donath M. Unsuspected osteomyelitis is
frequent in persistent diabetic foot ulcer and better diagnosed by MRI
than by 18F-FDG PET or 99mTc-MOAB. Journal of internal medicine 2008;
263: 99-106.
16. Newman L, Waller J, Palestro C, Schwartz M, Klein M, Hermann G,
Harrington E, Harrington M, Roman S, Stagnaro-Green A. Unsuspected
osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by
leukocyte scanning with indium in 111 oxyquinoline. JAMA 1991; 266:
1246-51.
17. Game F. Management of osteomyelitis of the foot in diabetes
mellitus. Nat Rev Endocrinol 2010; 6: 43-7.
18. Lavery L, Armstrong D, Wunderlich R, Mohler M, Wendel C, Lipsky B.
Risk factors for foot infections in individuals with diabetes. Diabetes
care 2006; 29: 1288-93.
19. Katsuhara Y, Ikeda S. Correlations Between SGLT-2 Inhibitors and
Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis
for Reporting Country and Concomitant Drugs. Clin Drug Investig 2021;
41: 235-43.
20. Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G,
Moretti U. Pharmacovigilance of sodium-glucose co-transporter-2
inhibitors: What a clinician should know on disproportionality analysis
of spontaneous reporting systems. Nutrition, metabolism, and
cardiovascular diseases : NMCD 2018; 28: 533-42.
21. Min J, Osborne V, Kowalski A, Prosperi M. Reported Adverse Events
with Painkillers: Data Mining of the US Food and Drug Administration
Adverse Events Reporting System. Drug safety 2018; 41: 313-20.
22. Moreland-Head LN, Coons JC, Seybert AL, Gray MP, Kane-Gill SL. Use
of Disproportionality Analysis to Identify Previously Unknown
Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug
Administration Adverse Event Reporting System (FAERS) Database. J
Cardiovasc Pharmacol Ther 2021; 26: 341-48.
23. Bate A, Lindquist M, Edwards I, Olsson S, Orre R, Lansner A, De
Freitas R. A Bayesian neural network method for adverse drug reaction
signal generation. European journal of clinical pharmacology 1998; 54:
315-21.
24. Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, He Z, Zhao W, Chen C, Qiu
K, Wu J. Association of glucose-lowering medications with cardiovascular
outcomes: an umbrella review and evidence map. The Lancet Diabetes &
Endocrinology 2020; 8: 192-205.
25. Bonora B, Raschi E, Avogaro A, Fadini G. SGLT-2 inhibitors and
atrial fibrillation in the Food and Drug Administration adverse event
reporting system. Cardiovascular diabetology 2021; 20: 39.
26. Pasquel F, Lansang M, Dhatariya K, Umpierrez G. Management of
diabetes and hyperglycaemia in the hospital. The lancet Diabetes &
endocrinology 2021; 9: 174-88.
27. Davies M, D’Alessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G,
Rossing P, Tsapas A, Wexler D, Buse J. Management of hyperglycaemia in
type 2 diabetes, 2018. A consensus report by the American Diabetes
Association (ADA) and the European Association for the Study of Diabetes
(EASD). Diabetologia 2018; 61: 2461-98.
28. Ramsey S, Newton K, Blough D, McCulloch D, Sandhu N, Reiber G,
Wagner E. Incidence, outcomes, and cost of foot ulcers in patients with
diabetes. Diabetes care 1999; 22: 382-7.
29. Eckman M, Greenfield S, Mackey W, Wong J, Kaplan S, Sullivan L,
Dukes K, Pauker S. Foot infections in diabetic patients. Decision and
cost-effectiveness analyses. JAMA 1995; 273: 712-20.
30. Kobayashi H, Fujita R, Hiratsuka S, Shimizu T, Sato D, Hamano H,
Iwasaki N, Takahata M. Differential effects of anti-RANKL monoclonal
antibody and zoledronic acid on necrotic bone in a murine model of
Staphylococcus aureus-induced osteomyelitis. Journal of orthopaedic
research : official publication of the Orthopaedic Research Society
2022; 40: 614-23.
31. Zhang L, Wang Y, Zhao J, Li Y, Chen H. Sex Differences in
Osteomyelitis of the Foot in Persons With Diabetes Mellitus: A
Meta-Analysis. Wound management & prevention 2021; 67: 19-25.
32. Almenoff J, Pattishall E, Gibbs T, DuMouchel W, Evans S, Yuen N.
Novel statistical tools for monitoring the safety of marketed drugs.
Clinical pharmacology and therapeutics 2007; 82: 157-66.
33. Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse
drug event reports for safety signals in Singapore - a comparison of
three different disproportionality measures. Expert Opin Drug Saf 2016;
15: 583-90.
34. Hou Y, Ye X, Wu G, Cheng G, Du X, He J. A comparison of
disproportionality analysis methods in national adverse drug reaction
databases of China. Expert Opin Drug Saf 2014; 13: 853-7.
35. Butalia S, Palda V, Sargeant R, Detsky A, Mourad O. Does this
patient with diabetes have osteomyelitis of the lower extremity? JAMA
2008; 299: 806-13.